Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Diamyd

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Diamyd Medical Secures $125M Equity Financing, Completes Phase 3
    Diamyd Medical Secures $125M Equity Financing, Completes Phase 3

    23 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-enters-into-equity-financing-agreements-with-new-us-sector-specialist-investors-for-up-to-usd-125-million-and-announces-full-enrollment-in-phase-3-trial-302721837.html

    PR NEWSWIRE
    23 Mar 2026
    Share Share
    Diamyd Medical Granted Key Retogatein US Patent
    Diamyd Medical Granted Key Retogatein US Patent

    09 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-receives-notice-of-allowance-for-key-retogatein-us-patent-302682399.html

    PR NEWSWIRE
    09 Feb 2026
    Share Share
    Diamyd Speeds Up Type 1 Diabetes Phase 3 Readout by 9 Months
    Diamyd Speeds Up Type 1 Diabetes Phase 3 Readout by 9 Months

    29 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-accelerates-primary-efficacy-readout-by-9-months-in-type-1-diabetes-phase-3-trial-following-fda-alignment-and-guidance-302650064.html

    PR NEWSWIRE
    29 Dec 2025
    Share Share
    Diamyd Medical's Phase 3 Type 1 Diabetes Trial Passes Final
    Diamyd Medical's Phase 3 Type 1 Diabetes Trial Passes Final

    14 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medicals-pivotal-phase-3-type-1-diabetes-trial-clears-last-safety-review-ahead-of-early-readout-in-march-2026-302615394.html

    PR NEWSWIRE
    14 Nov 2025
    Share Share
    Diamyd Medical highlights Type 1 Diabetes prevention, Phase 3
    Diamyd Medical highlights Type 1 Diabetes prevention, Phase 3

    21 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-highlights-opportunity-in-type-1-diabetes-prevention-adult-onset-market-and-upcoming-phase-3-readout-302433254.html

    PR NEWSWIRE
    21 Apr 2025
    Share Share
    Diamyd Medical Pursues Accelerated Approval For T1D Precision Medicine
    Diamyd Medical Pursues Accelerated Approval For T1D Precision Medicine

    09 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/diamyd-medical-to-pursue-accelerated-approval-pathway-for-type-1-diabetes-precision-medicine-302241745.html

    PR NEWSWIRE
    09 Sep 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.